Rob Weinkove is Clinical Director at the Malaghan Institute of Medical Research (MIMR), a Haematologist at Health New Zealand, and Honorary Professor at the University of Auckland. After studying medicine in Cambridge and London, he trained in clinical haematology in London and in Hannover, and undertook a PhD in immunology at the University of Otago.

Prof Weinkove leads a clinical and translational chimeric antigen receptor (CAR) T-cell programme at the Malaghan Institute. He was Principal Investigator of ENABLE-1, a phase 1 trial of a new third generation CAR T-cell therapy for B-cell lymphomas; a national phase 2 trial, ENABLE-2, is now enrolling. For BioOra, he provides clinical oversight for GMP-grade lentiviral vector and CAR T-cell manufacturing under Medsafe license. He is an active member of the Australasian Leukaemia & Lymphoma Group where he contributes to co-operative group and commercial clinical trials in the fields of B-cell malignancies and prevention of infection in the immunocompromised.